NEUROPSYCHOPHARMACOLOGY OF ALTERED CONSCIOUSNESS

意识改变的神经心理药理学

• 批准号: 7242646
• 负责人: Reese T. Jones
• 金额: $ 11.96万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1977
• 资助国家: 美国
• 起止时间: 1977-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7242646
• 关键词: 3,4-Methylenedioxyamphetamine; Accounting; Affect; Agonist; Anxiety; Attention; Autoreceptors; Behavioral; Biological Markers; Buprenorphine; Cannabinoids; Cardiovascular system; Class; Clinical Pharmacology; Clinical Research; Clinical Trials; Cocaine; Cocaine Dependence; Condition; Conscious; Contracts; Controlled Study; Cues; Dependence; Deuterium; Development; Disease; Dopamine; Dose; Dose-Limiting; Drug Addiction; Drug Exposure; Drug Kinetics; Drug Transport; Drug abuse; Drug usage; Goals; Grant; Hair; Health; Human; Human Volunteers; Individual Differences; Label; Laboratories; Lysergic Acid Diethylamide; Mental Depression; Methamphetamine; Modification; Moods; N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine; National Institute of Drug Abuse; Neurosecretory Systems; Numbers; Opiate Addiction; Pharmaceutical Preparations; Pharmacodynamics; Pharmacotherapy; Phase; Phase I Clinical Trials; Phenethylamine; Phenethylamines; Physiological; Pigments; Psychopharmacology; Psychotic Disorders; Psychotropic Drugs; Range; Relapse; Request for Applications; Research; Research Scientist Award; Role; Safety; Schizophrenia; Sebum; Self Administration; Skin; Skin Tissue; Sweat; Sweat Glands; Sweating; Testing; Tetrahydrocannabinol; Therapy Clinical Trials; Time; Withdrawal; behavior measurement; carbene; concept; craving; design; desire; dimoxamine; drug development; drug of abuse; ecstasy; indexing; innovation; interest; multidisciplinary; neurochemistry; neurophysiology; neuropsychological; novel; pramipexol; preclinical study; prevent; programs; psychologic; research study; response; skin pharmacology

DESCRIPTION (provided by applicant): This application requests continuation of a Research Scientist Award (K05). The broadest objectives are to understand why people take psychoactive drugs, what are expected or desired effects, what might account for unexpected or adverse consequences, and how can adverse consequences best be managed or prevented. How might tolerance and dependence determine differences in drug use and effects? How useful is phamacokinetic information for understanding differences in drug response? With support from other NIDA grants and contracts human laboratory experiments will study the pharmacokinetics and pharmacodynamics of cocaine, methamphetamine, cannabinoids 3,4-methylene-dioxymethamphetamine (MDMA) and interactions with other drugs. The cardiovascular, autonomic, neuroendocrine and subjective effects of MDMA and related of substituted phenethylamines will be compared to lysergic acid diethylamide (LSD). Modification of cocaine and methamphetamine tolerance and sensitization by new treatment medications will be studied. The pharmacokinetics of deuterium-labeled methamphetamine and tetrahydrocannabinol in hair and sweat will be characterized to better understand mechanisms and utility of hair and sweat for biomarkers of drug exposure. We will characterize the pharmacokinetics and dynamics of medications under development for pharmacotherapy of stimulant and other drug dependence in Phase I experiments. As possible, equal attention is given to psychological and behavioral measures, assessment of mood, neurophysiological and neurochemical indices. Emphasis is on understanding relationships between behavioral, physiologic and pharmacologic variables. Recognizing that people rarely limit drug taking to a single drug or class of drugs, development and application of research strategies appropriate to the study of multiple classes of drugs is preferred. Where possible, mechanisms and explanations for individual differences in drug effects are studied. Relationships between naturally occurring and drug-induced disorders, for example, depression, anxiety states and schizophrenia or other psychosis is a topic of interest. The studies are multidisciplinary. They involve only human volunteers. The research will further understanding psychoactive drug use, health consequences and management.

描述（由申请人提供）：本申请要求继续研究科学家奖（K 05）。 最广泛的目标是了解人们为什么服用精神活性药物，预期或期望的效果是什么，什么可能导致意外或不良后果，以及如何最好地管理或预防不良后果。 耐受性和依赖性如何决定药物使用和影响的差异？ 药代动力学信息对理解药物反应差异有多大作用？ 在NIDA其他赠款和合同的支持下，人体实验室实验将研究可卡因、甲基苯丙胺、大麻素3，4-亚甲基二氧甲基苯丙胺（MDMA）的药代动力学和药效学以及与其他药物的相互作用。 将比较MDMA和相关取代苯乙胺与麦角酰二乙胺（LSD）的心血管、自主神经、神经内分泌和主观效应。 将研究新治疗药物对可卡因和甲基苯丙胺耐受性和致敏性的改变。 氘标记的甲基苯丙胺和四氢大麻酚在头发和汗液中的药代动力学将被表征，以更好地理解头发和汗液作为药物暴露生物标志物的机制和效用。 我们将在I期实验中描述用于兴奋剂和其他药物依赖药物治疗的药物的药代动力学和动力学。 在可能的情况下，对心理和行为测量、情绪评估、神经生理学和神经化学指标给予同等重视。 重点是了解行为，生理和药理学变量之间的关系。 认识到人们很少将药物服用限制在单一药物或药物类别，因此最好开发和应用适合于多种药物研究的研究策略。 在可能的情况下，研究药物作用的个体差异的机制和解释。 自然发生的和药物引起的疾病之间的关系，例如，抑郁症，焦虑状态和精神分裂症或其他精神病是一个感兴趣的话题。 这些研究是多学科的。 他们只涉及人类志愿者。 这项研究将进一步了解精神活性药物的使用、健康后果和管理。